Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
---|
CEO | Ruiwen Huang |
IPO Date | Dec. 25, 2020 |
Location | |
Headquarters | No.99, Xintai 5th Road |
Employees | 33 |
Sector | Health Care |
Industries |
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email